Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024
January 09, 2024 at 06:30 am
Share
Inari Medical, Inc. provided revenue guidance for the fourth quarter of 2023 and full year of 2023 and 2024. For the quarter, company expects revenue to be at least $132.0 million, up approximately 22% year-over-year.
For the year 2023, company expects revenue to be at least $493.5 million, up approximately 29% over the full year 2022.
For the year 2024, company expects revenue of $580 million to $595 million, reflecting growth of approximately 17.5% to 20.5% over 2023.
Inari Medical, Inc. is a medical device company. The Companyâs products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
INARI MEDICAL, INC. 
